Effects of losartan and antiretroviral regimen containing raltegravir in fibrosis inflammation mediators, cardiovascular risk and neurocognitive disorders in HIV infected patients previously effectively treated. - N/A

Fundació Clínic de Recerca Biomèdica0 个研究点开始时间: 2012年1月11日最近更新: 2016年5月17日

适应症

试验速览

暂无简介。

•1. Patients older than 18 years.
•2. Patients with HIV infection in antiretroviral treatment with EFV / FTC / TDF with undetectable viral load (VL <37 copies) for at least 48 weeks.
•3. Nadir CD4 +> 250 cells/mm3.
•4. Patients, properly informed, give their written consent to participate in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 48
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Criteria for patients with AIDS.
•2. Patients with active opportunistic diseases.
•3. Patients coinfected with HCV.
•4. Patients without tonsillar tissue.
•5. Treatment with other drugs receptor antagonists or angiotensin II converting enzyme inhibitors, angiotensin II.
•6. Kidney failure.(Glomerular Filtration Rate (GFR < 60 mL/mn)
•7. Severe liver failure (PT> 60% ).
•8. Pregnant women
•9. Known hypersensitivity or contraindication to any study drug.
•10. determination of blood pressure (BP) <100/60 mmHg
•11. Hyponatremia with serum Na numbers <132 Meq / l
•12. History of chronic vomiting the last 6 months
•13. History of chronic diarrhea the last 6 months

发起方

Fundació Clínic de Recerca Biomèdica